KNSA
Price
$27.88
Change
+$0.44 (+1.60%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
2.03B
26 days until earnings call
SLRX
Price
$0.89
Change
-$0.01 (-1.11%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
1.89M
Interact to see
Advertisement

KNSA vs SLRX

Header iconKNSA vs SLRX Comparison
Open Charts KNSA vs SLRXBanner chart's image
Kiniksa Pharmaceuticals International
Price$27.88
Change+$0.44 (+1.60%)
Volume$103.34K
Capitalization2.03B
Salarius Pharmaceuticals
Price$0.89
Change-$0.01 (-1.11%)
Volume$100
Capitalization1.89M
KNSA vs SLRX Comparison Chart in %
Loading...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KNSA vs. SLRX commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KNSA is a Hold and SLRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (KNSA: $27.88 vs. SLRX: $0.89)
Brand notoriety: KNSA and SLRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KNSA: 65% vs. SLRX: 3%
Market capitalization -- KNSA: $2.03B vs. SLRX: $1.89M
KNSA [@Biotechnology] is valued at $2.03B. SLRX’s [@Biotechnology] market capitalization is $1.89M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KNSA’s FA Score shows that 1 FA rating(s) are green whileSLRX’s FA Score has 0 green FA rating(s).

  • KNSA’s FA Score: 1 green, 4 red.
  • SLRX’s FA Score: 0 green, 5 red.
According to our system of comparison, KNSA is a better buy in the long-term than SLRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KNSA’s TA Score shows that 3 TA indicator(s) are bullish while SLRX’s TA Score has 4 bullish TA indicator(s).

  • KNSA’s TA Score: 3 bullish, 5 bearish.
  • SLRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both KNSA and SLRX are a bad buy in the short-term.

Price Growth

KNSA (@Biotechnology) experienced а -2.14% price change this week, while SLRX (@Biotechnology) price change was -10.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

KNSA is expected to report earnings on Jul 29, 2025.

SLRX is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($2.03B) has a higher market cap than SLRX($1.89M). KNSA YTD gains are higher at: 40.950 vs. SLRX (-51.723). SLRX has higher annual earnings (EBITDA): -5.68M vs. KNSA (-14.23M). KNSA has more cash in the bank: 268M vs. SLRX (1.8M). SLRX has less debt than KNSA: SLRX (112K) vs KNSA (9.92M). KNSA has higher revenues than SLRX: KNSA (481M) vs SLRX (0).
KNSASLRXKNSA / SLRX
Capitalization2.03B1.89M107,619%
EBITDA-14.23M-5.68M251%
Gain YTD40.950-51.723-79%
P/E Ratio164.54N/A-
Revenue481M0-
Total Cash268M1.8M14,905%
Total Debt9.92M112K8,853%
FUNDAMENTALS RATINGS
KNSA vs SLRX: Fundamental Ratings
KNSA
SLRX
OUTLOOK RATING
1..100
589
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
91100
PRICE GROWTH RATING
1..100
4161
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
34n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLRX's Valuation (82) in the null industry is in the same range as KNSA (84) in the Pharmaceuticals Major industry. This means that SLRX’s stock grew similarly to KNSA’s over the last 12 months.

KNSA's Profit vs Risk Rating (72) in the Pharmaceuticals Major industry is in the same range as SLRX (100) in the null industry. This means that KNSA’s stock grew similarly to SLRX’s over the last 12 months.

KNSA's SMR Rating (91) in the Pharmaceuticals Major industry is in the same range as SLRX (100) in the null industry. This means that KNSA’s stock grew similarly to SLRX’s over the last 12 months.

KNSA's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as SLRX (61) in the null industry. This means that KNSA’s stock grew similarly to SLRX’s over the last 12 months.

KNSA's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for SLRX (100) in the null industry. This means that KNSA’s stock grew significantly faster than SLRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KNSASLRX
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 11 days ago
74%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAIDX56.27N/A
N/A
Fidelity Advisor International Discv A
MEIFX13.89N/A
N/A
Meridian Hedged Equity Legacy
WPSZX56.09N/A
N/A
AB Concentrated Growth Z
NMUEX10.95N/A
N/A
Neuberger Berman Multi-Cap Opp E
MBCNX16.70N/A
N/A
MassMutual Blue Chip Growth R3

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with ABVC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then ABVC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
+1.60%
ABVC - KNSA
40%
Loosely correlated
+0.32%
COYA - KNSA
40%
Loosely correlated
+3.11%
BEAM - KNSA
36%
Loosely correlated
+0.65%
AMRN - KNSA
36%
Loosely correlated
+0.48%
CPRX - KNSA
35%
Loosely correlated
+0.05%
More

SLRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLRX has been closely correlated with MBIO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if SLRX jumps, then MBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLRX
1D Price
Change %
SLRX100%
-1.17%
MBIO - SLRX
71%
Closely correlated
-4.03%
AZTR - SLRX
38%
Loosely correlated
-1.45%
PHIO - SLRX
32%
Poorly correlated
-3.23%
NRSN - SLRX
32%
Poorly correlated
+0.53%
KNSA - SLRX
29%
Poorly correlated
+1.60%
More